Short answer
ARTIVION, INC. (AORT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references Exhibit 99.1 for Artivion’s fiscal 2026 results and accompanying press release.
ARTIVION, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references Exhibit 99.1 for Artivion’s fiscal 2026 results and accompanying press release
- Forward-looking statements subject to material execution risks and potential deviation from management expectations
- Investors should review Exhibit 99.1 and recent SEC filings for financial results and risk factors
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $125.8M, up 11% GAAP and 9% constant currency, led by On-X growth 18% and stent graft growth 12%
- GAAP net loss $(13.5)M, or $(0.28) per share, versus $1.3M profit; non-GAAP EPS declined to $0.13 from $0.24
- Adjusted EBITDA rose 7% to $26.4M, despite $15.5M in business development, integration, and severance costs
- FDA approval of AMDS and Endospan acquisition expand Artivion’s aortic-arch portfolio, while NEXUS supports three additional PMA programs
- Full-year guidance reiterated: revenue $480–$496M and adjusted EBITDA $92–$99M, including approximately $8M of Endospan-related expense
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARTIVION, INC. 8-K filings
Get the next AORT 8-K as it lands
Follow AORT for push alerts, or ask the research agent what this filing means.